Allogeneic transplantation for peripheral and cutaneous T-cell lymphomas

Few studies have evaluated the role of allogeneic stem cell transplantation (SCT) in peripheral Tcell lymphomas (PTCL). Recent reports have evaluated allogeneic SCT exclusively in relapsed setting and showed an evidence for a graft-versus-lymphoma effect (GVL). In this report we extended our previous observations to 38 patients. All patients received several courses of debulkying chemotherapy followed by allogeneic SCT with a reduced intensity conditioning (RIC) regimen. Patients’ median age was 45 years (range, 15-64). Histologic PTCL subtypes included: unspecified (n=15), ALCL (n=9), AILD (n=5), intestinal (n=3), other subtypes (n=6). Twenty-eight pts (74%) received transplant from HLA-identical sibling donors, 5 from haploidentical donors (13%) and 5 from unrelated donors (13%). The median time from diagnosis to allogeneic SCT was 16.4 months. Twenty-one patients (55%) had failed a previous autologous SCT. Twenty-eight (73%) had chemosensitive disease (n=13 in CR, n=15 in PR). Ten patients received low dose alemtuzumab in the conditioning regimen for GVHD prophylaxis.